BRIEF-ARS Pharmaceuticals Submits Response To FDA Complete Response Letter For neffy (Epinephrine Nasal Spray)

Reuters04-03

April 3 (Reuters) - ARS Pharmaceuticals Inc :

* ARS PHARMACEUTICALS SUBMITS RESPONSE TO FDA COMPLETE RESPONSE LETTER FOR NEFFY® (EPINEPHRINE NASAL SPRAY)

* ARS PHARMACEUTICALS INC - SUBMISSION OF CRL RESPONSE TRIGGERS UP TO SIX-MONTH REVIEW PERIOD BY FDA

* ARS PHARMACEUTICALS INC - ARS PHARMA ANTICIPATES AN FDA REVIEW PERIOD OF UP TO SIX MONTHS, AND PDUFA DATE IS ANTICIPATED TO BE OCTOBER 2, 2024

* ARS PHARMACEUTICALS INC - RESPONSE ADDRESSES ALL ADDITIONAL REQUESTS IN FDA CRL

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2424844488?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-03 22:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2424844488","market":"us","top_or_hot":-1,"title":"BRIEF-ARS Pharmaceuticals Submits Response To FDA Complete Response Letter For neffy (Epinephrine Nasal Spray)","media":"Reuters","content":"<html><body><p>April 3 (Reuters) - ARS Pharmaceuticals Inc   :</p><p>   * ARS PHARMACEUTICALS SUBMITS RESPONSE TO FDA COMPLETE RESPONSE LETTER FOR NEFFY® (EPINEPHRINE NASAL SPRAY)</p><p>   * <a href=\"https://laohu8.com/S/SPRY\">ARS PHARMACEUTICALS INC</a> - SUBMISSION OF CRL RESPONSE TRIGGERS UP TO SIX-MONTH REVIEW PERIOD BY FDA</p><p>   * ARS PHARMACEUTICALS INC - ARS PHARMA ANTICIPATES AN FDA REVIEW PERIOD OF UP TO SIX MONTHS, AND PDUFA DATE IS ANTICIPATED TO BE OCTOBER 2, 2024</p><p>   * ARS PHARMACEUTICALS INC - RESPONSE ADDRESSES ALL ADDITIONAL REQUESTS IN FDA CRL</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-ARS Pharmaceuticals Submits Response To FDA Complete Response Letter For neffy (Epinephrine Nasal Spray)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-ARS Pharmaceuticals Submits Response To FDA Complete Response Letter For neffy (Epinephrine Nasal Spray)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-03 22:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>April 3 (Reuters) - ARS Pharmaceuticals Inc   :   * ARS PHARMACEUTICALS SUBMITS RESPONSE TO FDA COMPLETE RESPONSE LETTER FOR NEFFY® (EPINEPHRINE NASAL SPRAY)   * ARS PHARMACEUTICALS INC - SUBMISSION ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SPRY","symbol_name":"ARS PHARMACEUTICALS INC","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2424844488","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2424844488","pubTimestamp":1712154213,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 3  - ARS Pharmaceuticals Inc   :   * ARS PHARMACEUTICALS SUBMITS RESPONSE TO FDA COMPLETE RESPONSE LETTER FOR NEFFY    * ARS PHARMACEUTICALS INC - SUBMISSION OF CRL RESPONSE TRIGGERS UP TO SIX-MONTH REVIEW PERIOD BY FDA   * ARS PHARMACEUTICALS INC - ARS PHARMA ANTICIPATES AN FDA REVIEW PERIOD OF UP TO SIX MONTHS, AND PDUFA DATE IS ANTICIPATED TO BE OCTOBER 2, 2024   * ARS PHARMACEUTICALS INC - RESPONSE ADDRESSES ALL ADDITIONAL REQUESTS IN FDA CRLSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SPRY":"ARS PHARMACEUTICALS INC","BK4139":"生物科技"},"translate_title":"ARS Pharmaceuticals向FDA提交关于neffy（肾上腺素鼻喷剂）的完整回复信","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRY":0.9},"content_text":"April 3 (Reuters) - ARS Pharmaceuticals Inc   :   * ARS PHARMACEUTICALS SUBMITS RESPONSE TO FDA COMPLETE RESPONSE LETTER FOR NEFFY® (EPINEPHRINE NASAL SPRAY)   * ARS PHARMACEUTICALS INC - SUBMISSION OF CRL RESPONSE TRIGGERS UP TO SIX-MONTH REVIEW PERIOD BY FDA   * ARS PHARMACEUTICALS INC - ARS PHARMA ANTICIPATES AN FDA REVIEW PERIOD OF UP TO SIX MONTHS, AND PDUFA DATE IS ANTICIPATED TO BE OCTOBER 2, 2024   * ARS PHARMACEUTICALS INC - RESPONSE ADDRESSES ALL ADDITIONAL REQUESTS IN FDA CRLSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2424844488"}